Response to comments on "multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems" [2]

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1387-

  Lau, Yvonne Y ^a   Okochi, Hideaki ^a   Huang, Yong ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; DRUG METABOLITE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; REPAGLINIDE; RIFAMPICIN;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LETTER; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL;

EID: 33644784915     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.099473     Document Type: Letter

References (6)

1. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, and Brøsen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109-114.
2. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
3. Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256.
4. Lam JL and Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311-1316.
5. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
6. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.